| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Eva Germovsek | Q56046230 |
| Charlotte I Barker | Q56046240 | ||
| Jodi M Lestner | Q56856379 | ||
| Rollo L Hoare | Q60529522 | ||
| Joanna Lewis | Q64685445 | ||
| P2093 | author name string | Joseph F Standing | |
| P2860 | cites work | Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients | Q68202648 |
| Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study | Q68692675 | ||
| Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates | Q68761188 | ||
| Pharmacokinetics of amphotericin B in infants and children | Q69755066 | ||
| Oral acyclovir to prevent dissemination of varicella in immunocompromised children | Q70615489 | ||
| Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group | Q73166594 | ||
| Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000 | Q74599986 | ||
| Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life | Q77402921 | ||
| Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin | Q78342706 | ||
| Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies | Q79160640 | ||
| Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates | Q79735915 | ||
| Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection | Q80407528 | ||
| Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality | Q81436465 | ||
| Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients | Q82143092 | ||
| CD31+ cell percentage correlation with speed of CD4+ T-cell count recovery in HIV-infected adults is reversed in children: higher thymic output may be responsible | Q83852425 | ||
| Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children | Q84521307 | ||
| Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations | Q84540787 | ||
| Reconstitution rate of absolute CD8+ T lymphocyte counts affects overall survival after pediatric allogeneic hematopoietic stem cell transplantation | Q84570852 | ||
| Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing Cardiopulmonary Bypass | Q85073452 | ||
| Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases | Q24542404 | ||
| Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections | Q24594815 | ||
| Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants | Q24626231 | ||
| Recommended reading in population pharmacokinetic pharmacodynamics | Q24647906 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time | Q29547822 | ||
| Fluconazole prophylaxis against fungal colonization and infection in preterm infants | Q30308442 | ||
| Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates | Q30310834 | ||
| Oseltamivir in the management of influenza. | Q30351736 | ||
| Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection | Q30408582 | ||
| Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. | Q30409445 | ||
| Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children | Q30626863 | ||
| Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant | Q31832758 | ||
| Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies | Q33392206 | ||
| Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. | Q33501181 | ||
| Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy | Q33510903 | ||
| Voriconazole pharmacokinetics and pharmacodynamics in children | Q33577291 | ||
| Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. | Q33690036 | ||
| The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. | Q38068293 | ||
| Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam | Q38075482 | ||
| Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children | Q38107016 | ||
| Maximum likelihood estimation of long-term HIV dynamic models and antiviral response | Q38440550 | ||
| Nephrotoxicity of aminoglycoside antibiotics. | Q38616214 | ||
| Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis | Q39477254 | ||
| Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. | Q39557816 | ||
| Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children | Q39766442 | ||
| Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. | Q39781130 | ||
| Pharmacokinetics of teicoplanin in pediatric patients | Q39818673 | ||
| Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 | ||
| Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections | Q39913232 | ||
| Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients | Q39920233 | ||
| Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics | Q40157128 | ||
| Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants | Q40326667 | ||
| Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. | Q40552200 | ||
| Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies | Q40777942 | ||
| Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen | Q40794081 | ||
| Pharmacokinetics of amikacin in infants and pre-school children | Q41598345 | ||
| Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients | Q42083118 | ||
| Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring | Q42282104 | ||
| Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. | Q42286838 | ||
| Population pharmacokinetics of ciprofloxacin in pediatric patients | Q42603473 | ||
| The pharmacokinetics of meropenem in infants and children: a population analysis | Q42624959 | ||
| Vancomycin population pharmacokinetics in neonates | Q42626054 | ||
| Tobramycin population pharmacokinetics in neonates. | Q42666715 | ||
| Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials | Q42671287 | ||
| Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants | Q42684527 | ||
| Population pharmacokinetics of gentamicin in premature newborns. | Q42688816 | ||
| Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease | Q42696550 | ||
| Drug dosing in renal disease | Q42738036 | ||
| Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics | Q42996149 | ||
| Pharmacokinetics and dose requirements of vancomycin in neonates | Q43097632 | ||
| Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients | Q43186296 | ||
| A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections | Q43278204 | ||
| Toxicodynamics of itraconazole: implications for therapeutic drug monitoring | Q43291845 | ||
| Score tests for exploring complex models: application to HIV dynamics models | Q43473035 | ||
| Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model | Q43640101 | ||
| Pharmacokinetics of ganciclovir in renal transplant children | Q43710488 | ||
| High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection | Q43783467 | ||
| Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients | Q43849610 | ||
| Pharmacokinetics of ganciclovir in pediatric renal transplant recipients | Q44300481 | ||
| Response to combination antiretroviral therapy: variation by age. | Q44396687 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children | Q44514184 | ||
| A Bayesian approach to parameter estimation in HIV dynamical models | Q44542356 | ||
| Dosing considerations for oral acyclovir following neonatal herpes disease | Q44557280 | ||
| Treatment monitoring of HIV-infected patients based on mechanistic models | Q44581468 | ||
| Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life | Q44700606 | ||
| Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. | Q44723819 | ||
| Valacyclovir and acyclovir pharmacokinetics in immunocompromised children | Q33776931 | ||
| Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children | Q33826417 | ||
| Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. | Q33826426 | ||
| Population pharmacokinetics of micafungin in neonates and young infants | Q33876608 | ||
| The bactericidal action of penicillin: new clues to an unsolved mystery | Q33934194 | ||
| Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 | ||
| Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis | Q33981154 | ||
| Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections | Q33983119 | ||
| Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis | Q34111158 | ||
| Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents | Q34123805 | ||
| Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis | Q34182776 | ||
| Population pharmacokinetics of amphotericin B lipid complex in neonates | Q34228332 | ||
| Aminoglycoside adaptive resistance: importance for effective dosage regimens | Q34277787 | ||
| Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 | ||
| Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections | Q34352100 | ||
| Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline | Q34381352 | ||
| Fluconazole loading dose pharmacokinetics and safety in infants | Q34807770 | ||
| Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients | Q34932330 | ||
| Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment | Q34937231 | ||
| In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis | Q35091285 | ||
| Continuous infusion of high-dose acyclovir for serious herpesvirus infections | Q35345243 | ||
| Pharmacokinetics of amphotericin B in children | Q35360830 | ||
| Pharmacokinetics of acyclovir suspension in infants and children | Q35543240 | ||
| Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults | Q35598464 | ||
| Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults | Q35598532 | ||
| Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid | Q35623055 | ||
| Posaconazole plasma concentrations in juvenile patients with invasive fungal infection | Q35647678 | ||
| Population pharmacokinetics of voriconazole in adults | Q35666490 | ||
| The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease | Q35683931 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants | Q35867330 | ||
| Population pharmacokinetics I: background, concepts, and models | Q35870696 | ||
| The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. | Q35874039 | ||
| Population pharmacokinetics II: estimation methods | Q35887615 | ||
| A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients | Q44775929 | ||
| Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal | Q44897892 | ||
| Pharmacokinetics of teicoplanin in an ICU population of children and infants | Q45179807 | ||
| Ganciclovir treatment in children: evidence of subtherapeutic levels | Q45308623 | ||
| Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children | Q45403029 | ||
| Neonatal acyclovir pharmacokinetics in patients with herpes virus infections | Q45800069 | ||
| Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. | Q45984535 | ||
| Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. | Q46078844 | ||
| Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate | Q46470310 | ||
| Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone | Q46601415 | ||
| CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire | Q46614246 | ||
| Voriconazole in newborns. | Q46681387 | ||
| Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes | Q46826187 | ||
| Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients | Q46882759 | ||
| Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants | Q47298320 | ||
| Population pharmacokinetics of gentamicin in South African newborns | Q47435744 | ||
| Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation | Q49151311 | ||
| Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. | Q50581300 | ||
| Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. | Q50771334 | ||
| Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. | Q50975449 | ||
| Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. | Q50976272 | ||
| Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation. | Q51625200 | ||
| Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. | Q51756288 | ||
| Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. | Q51788059 | ||
| Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting". | Q51912232 | ||
| Maximum likelihood estimation in dynamical models of HIV. | Q51915380 | ||
| Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. | Q51966954 | ||
| Single dose pharmacokinetics of linezolid in infants and children. | Q52142272 | ||
| Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. | Q52247289 | ||
| In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. | Q52429639 | ||
| The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. | Q53267898 | ||
| Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. | Q53921471 | ||
| Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion | Q56530204 | ||
| Metronidazole Population Pharmacokinetics in Preterm Neonates Using Dried Blood-Spot Sampling | Q60428210 | ||
| Influence of Intrauterine Maturation on the Pharmacokinetics of Amikacin in the Neonatal Period | Q61713352 | ||
| Multivariate analyses of immune reconstitution in children after allo-SCT: risk-estimation based on age-matched leukocyte sub-populations | Q61907216 | ||
| Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis | Q61912446 | ||
| Pharmacokinetics of teicoplanin in children | Q61943786 | ||
| Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+CD3+ count reconstitution is associated with survival | Q63386801 | ||
| A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients | Q37390905 | ||
| Population pharmacokinetics and optimal design of paediatric studies for famciclovir. | Q37427931 | ||
| Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis | Q37624520 | ||
| PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection | Q37624875 | ||
| Pharmacokinetic optimization of antiretroviral therapy in children and adolescents | Q37835819 | ||
| Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. | Q37927016 | ||
| Kinetics and dose calculations of amikacin in the newborn | Q67462285 | ||
| Itraconazole therapy for disseminated candidiasis in a very low birthweight neonate | Q67493977 | ||
| Population pharmacokinetics of gentamicin in premature infants | Q67564632 | ||
| Safety and pharmacokinetics of fluconazole in children with neoplastic diseases | Q68136211 | ||
| Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents | Q35912756 | ||
| Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies | Q35928858 | ||
| Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children | Q35973543 | ||
| Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults | Q36018595 | ||
| Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance | Q36024899 | ||
| New dosing strategies for antibacterial agents in the neonate | Q36035169 | ||
| Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing | Q36094957 | ||
| Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia | Q36094974 | ||
| Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. | Q36095091 | ||
| Antiviral therapies in children: has their time arrived? | Q36145050 | ||
| Short versus long infusion of meropenem in very-low-birth-weight neonates | Q36172523 | ||
| An Evaluation of Gentamicin, Tobramycin, and Amikacin Pharmacokinetic/Pharmacodynamic Parameters in HIV-Infected Children | Q36311367 | ||
| Population clinical pharmacology of children: modelling covariate effects. | Q36522932 | ||
| Population clinical pharmacology of children: general principles. | Q36522936 | ||
| Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study | Q36536423 | ||
| Paediatric use of mycophenolate mofetil | Q36562448 | ||
| Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists | Q36582692 | ||
| Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza | Q36584645 | ||
| Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation | Q36645945 | ||
| Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? | Q36853968 | ||
| Pharmacodynamic implications for use of antifungal agents | Q36872633 | ||
| Ciclosporin kinetics in children after stem cell transplantation | Q36922221 | ||
| Optimizing drug development of anti-cancer drugs in children using modelling and simulation | Q36987975 | ||
| Facilitation of drug evaluation in children by population methods and modelling | Q37108169 | ||
| Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. | Q37115709 | ||
| Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera | Q37144784 | ||
| Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection | Q37190818 | ||
| Antifungal therapeutic drug monitoring: established and emerging indications | Q37310029 | ||
| Therapeutic drug monitoring for triazoles | Q37315204 | ||
| Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. | Q37315405 | ||
| Meropenem pharmacokinetics in the newborn. | Q37333159 | ||
| Pharmacokinetics of alemtuzumab and the relevance in clinical practice | Q37340406 | ||
| Homeostasis of naive and memory T cells | Q37356053 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| infection | Q166231 | ||
| immunology | Q101929 | ||
| infectious disease | Q18123741 | ||
| pharmacodynamics | Q725307 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 127-139 | |
| P577 | publication date | 2014-01-17 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology | |
| P478 | volume | 73 |
| Q37358644 | A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants |
| Q31119393 | An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data |
| Q38857191 | Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. |
| Q38641774 | Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis. |
| Q47689223 | Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. |
| Q52637932 | Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition. |
| Q36322918 | Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children |
| Q50465181 | Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations |
| Q40786820 | Paediatric Virology: A new paediatric subspecialty? A proposal at the Workshop on Paediatric Virology, Athens, October 10, 2015. |
| Q52575612 | Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. |
| Q38696468 | Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates |
| Q90226052 | Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants |
| Q41494950 | Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example |
| Q35105787 | Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study |
| Q55360869 | Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. |
Search more.